research Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.
Search
forLearn
0 / 0 results — no results
Research
4 / 4 resultsresearch Pharmaceutical and Non-Pharmaceutical Treatments for Migraine: A Systematic Review of Efficacy and Safety
Both new medications and non-drug treatments can effectively manage migraines with fewer side effects.
research Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients With Rosacea: An Exploratory Comparative Case Series
CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.
research Cyclosporine-Induced Alopecia: A Case Report, FDA Adverse Event Reporting System Analysis and Literature Assessment
Cyclosporine may cause hair loss, so patients need monitoring.
Community Join
0 / 0 results — no results